{"id":"W2546600532","doi":"10.1111/jdv.14033","title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3","year":2016,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"ca_institutions":"Guenther Dermatology Research Centre; Western University","funders":"Universidade Católica de Brasília; Regeneron Pharmaceuticals; Roche; American Society for Parenteral and Enteral Nutrition; Novartis; Merck; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer; Baxalta; Schering-Plough; AbbVie; Biogen Idec","keywords":"Ixekizumab; Medicine; Etanercept; Placebo; Psoriasis; Plaque psoriasis; Dermatology; Internal medicine; Psoriatic arthritis; Secukinumab; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002536837,0.0007628066,0.001811691,0.0002292344,0.0002596214,0.000732725,0.0005120455,0.0007877087,0.003657643],"category_scores_gemma":[0.001975436,0.0003218613,0.00231387,0.0003323219,0.0005974811,0.000500561,0.0002287899,0.001388558,0.0003010288],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005016728,"about_ca_system_score_gemma":0.0007078333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006098403,"about_ca_topic_score_gemma":0.001773005,"domain_scores_codex":[0.9990742,0.0005464237,0.00009572442,0.00009749993,0.0001013538,0.00008470892],"domain_scores_gemma":[0.9986072,0.0005401354,0.0004101518,0.00009573151,0.00009604151,0.0002508035],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9405222,0.007659666,0.002696003,0.001237392,0.00238553,0.00003373583,0.00007919951,0.000281069,0.004742371,0.00006292496,0.0009622425,0.03933751],"study_design_scores_gemma":[0.8897144,0.09550599,0.01114605,0.00009248468,0.001512712,0.0001021591,0.00004126726,0.0002632084,0.0007939183,0.00009962539,0.0007100127,0.00001815677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879953,0.00876007,0.0003089925,0.0003406015,0.0001662473,0.0008081211,0.0005615499,0.00004356124,0.001015482],"genre_scores_gemma":[0.9922415,0.004142562,0.0007433064,0.0005462165,0.0003054625,0.0005907149,0.0007477231,0.00001248887,0.0006702201],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003657643,"threshold_uncertainty_score":0.01341623,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01729171059612685,"score_gpt":0.2399895872063726,"score_spread":0.2226978766102457,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}